glp 1 heart failure Effects of Glucagon-Like Peptide Receptor Agonist Initiation in Patients With With Reduced Ejection Fraction and Implantable Cardiac Devices Can GLP-1 agonists treat cardiovascular

Description

While generally well tolerated, gastrointestinal side effects remain the most frequently reported, particularly during initial dose escalation

The decision, buried within the Department of Health Care Services (DHCS) cost-saving adjustments, comes after a year in which these drugs accounted for more than $1.6 billion in Medicaid reimbursements statewide

doi: 10.2337/dc12-2454 51 WildingJPHBatterhamRLCalannaSDaviesMVan GaalLFLingvayIet al

KFFs own numbers show that even among Medicares roughly 69 million beneficiaries, only about one in eighteen currently meets the Bridges BMI and health-history requirements